A Phase IV, Open-Label Study Evaluating Safety And Efficacy Of Subcutaneous Guselkumab In Indian Patients With Psoriatic Arthritis (Ahmedabad)

A Phase IV, Open-Label Study Evaluating Safety And Efficacy Of Subcutaneous Guselkumab In Indian Patients With Psoriatic Arthritis (Ahmedabad)

13 Aug
|
DecenTrialz
|
Ahmedabad

13 Aug

DecenTrialz

Ahmedabad

Actively Recruiting

Phase 4

Age: 18Years +

All Genders

ID07141004

A Phase IV, Open-Label Study Evaluating Safety and Efficacy of Subcutaneous Guselkumab in Indian Patients With Psoriatic Arthritis

Led by Johnson & Johnson Private Limited

Updated on 2026-06-05

100

Participants Needed

10

Research Sites

14 weeks

Total Duration

On this page

AI-Summary

Brief Title

Who Can Participate

AI-Screening

Your Study Journey

Trial Site Locations

Research Team

How is the study designed?

Similar Trials

Frequently Asked Questions

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of guselkumab treatment in adults with psoriatic arthritis PsA, a chronic autoimmune disease causing joint inflammation. This Phase IV, open-label study focuses on Indian patients whose arthritis symptoms have not adequately improved with standard treatments. The study aims to gather significant information on adverse events and how well the treatment works in this specific group.



Participants will receive guselkumab through subcutaneous injections given at Weeks 0, 4, 12, and 20. This treatment schedule is designed to assess the response over a period of time. The study does not include a comparison group and is open-label, meaning both researchers and participants know the treatment being given. During the study, participants will be monitored for safety by recording any adverse events up to 32 weeks. Effectiveness will be measured by response rates at Weeks 12 and 24 and changes in inflammation markers CRP levels. Regular assessments will include physical exams, medical history, vital signs, and laboratory tests. The total participation period extends up to approximately 32 weeks, with close follow-up to evaluate both safety and treatment impact.

CONDITIONS

Brief Title

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

Who Can Participate

Age: 18Years +

All Genders

Eli

📌 A Phase IV, Open-Label Study Evaluating Safety And Efficacy Of Subcutaneous Guselkumab In Indian Patients With Psoriatic Arthritis (Ahmedabad)
🏢 DecenTrialz
📍 Ahmedabad

Reply to this offer

Impress this employer describing Your skills and abilities, fill out the form below and leave Your personal touch in the presentation letter.

Subscribe to this job alert:

Get the latest job offers by email for: a phase iv, open-label study evaluating safety and efficacy of subcutaneous guselkumab in indian patients with psoriatic arthritis (ahmedabad) / ahmedabad

Subscribe to this job alert:

Get the latest job offers by email for: a phase iv, open-label study evaluating safety and efficacy of subcutaneous guselkumab in indian patients with psoriatic arthritis (ahmedabad) / ahmedabad